In this volume, we delve into the potential benefits of balovaptan—an oral selective vasopressin 1a receptor antagonist—as a groundbreaking solution for enhancing socialization and communication in pediatric ASD. We also explore the burning question of whether frequently prescribed ADHD medications carry an increased risk for cardiovascular disease. Furthermore, we examine the implications of being younger within a school group and the significance of long-acting antipsychotics in pediatric populations. Lastly, we investigate the factors driving the use of pharmacologic restraint in pediatric settings. What are the underlying causes, and how can they be addressed?
- Provider:Medical Academy, LLC
- Activity Link: https://psychopharmacologyinstitute.com/publication/tic-disorders-in-children-and-adolescents-2700?utm_source=PDF+CME+Program&utm_medium=PDF+CME+Program&utm_campaign=PDF+CME+Program
- Start Date: 2023-04-01 05:00:00
- End Date: 2023-04-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Knowledge, Learner Performance
- Provider Ship: Jointly Provided
- Registration: Limited
Subscribe
Login
0 Comments
Oldest